- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Toshiba's Latest Aquilion CT Receives FDA Clearance
The Aquilion Prime CT was designed for facilities that need to perform a wide variety of advanced clinical exams and produce high-quality clinical images with reduced radiation exposure, the company said.
The latest addition to Toshiba’s Aquilion CT product line has received FDA 510(k) clearance, the company announced.
The Aquilion Prime CT was designed for healthcare facilities that need to perform a wide variety of advanced clinical exams and produce high-quality clinical images with reduced radiation exposure, according to Toshiba America Medical Systems, Inc. The system has double-slice technology and the coneXact reconstruction algorithm, and can generate 160 unique slices per rotation, enhancing MPR and 3-D-rendered images.
The Aquilion Prime features an 80-row, 0.5 mm detector, a 7.5 MHU large-capacity tube, and a 0.35-second scanning. This allows for rapid data acquisition and shorter scan times, and the faster reconstruction aims to improve throughput, the company said. The system has a 78-cm aperture gantry, and a 660-pound patient-weight capacity couch.
The system features the Adaptive Iterative Dose Reduction, the iterative process for reducing noise from the image, and NEMA XR 25 Dose Check software, aimed at increasing user awareness of dose.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
